VeriStrat testing
Jump to navigation
Jump to search
Indications
- non-small cell lung cancer without EGFR mutation
- predicts response to EGFR tyrosine kinase inhibitors in patients who fail platinum-based chemotherapy
Procedure
- multivariate proteomic test
- results available within 72 hours
More general terms
References
- ↑ Nelson R VeriStrat Testing Reduces Costs in NSCLC. Medscape - Apr 10, 2017. http://www.medscape.com/viewarticle/878395
- ↑ Akerley WL, Arnaud AM, Reddy B, Page RD Impact of a multivariate serum-based proteomic test on physician treatment recommendations for advanced non-small- cell lung cancer. Curr Med Res Opin. 2017 Mar 16:1-7 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/28277859 <Internet> http://www.tandfonline.com/doi/abs/10.1080/03007995.2017.1301903